Wells Fargo Downgrades uniQure BV (QURE) to Equal Weight

Wells Fargo analyst Yanan Zhu downgraded uniQure BV (NASDAQ: QURE) from Overweight to Equal Weight with a price target of $15.00 (from $60.00).

The analyst comments: "QURE on Feb 27 received final minutes from FDA regarding a Type A meeting that was held on Jan 30. FDA stated it cannot agree that data from the P1/2 studies, compared to an external control (EC), are sufficient to provide the primary evidence of effectiveness required to support a BLA filing. FDA strongly recommended the company to conduct a prospective, randomized, double-blind, sham surgery- controlled study. We are downgrading our rating from Overweight to Equal Weight and lowering our PT from $60 to $15 based on updated model assumption on Huntington's disease program POS and launch timeline."

For an analyst ratings summary and ratings history on uniQure BV click here. For more ratings news on uniQure BV click here.

Shares of uniQure BV closed at $10.50 yesterday.

You May Also Be Interested In

• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
• UBS Reiterates Buy Rating on Hilton Worldwide (HLT)